Navigation Links
DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX'
Date:9/30/2009

PRINCETON, N.J., Sept. 30 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: SNGX), a late-stage biotechnology company, announced today that it has completed a corporate name change from DOR BioPharma, Inc. to Soligenix, Inc. (Soligenix or the Company). As a result of the name change, the Company's shares of common stock will immediately begin trading under the new ticker symbol "SNGX" as of today.

"We are pleased to announce the name change of our company to Soligenix," stated Christopher J. Schaber, Ph.D., President and CEO of Soligenix. "The name 'Soligenix' is derived in part from the Latin word 'Solis,' meaning sun. The name change heralds the new corporate stability and direction that we have worked hard to establish over the last several years."

Dr. Schaber continued, "We are also looking forward to the imminent initiation of our confirmatory Phase 3 clinical trial of orBec® in GI GVHD under a Special Protocol Assessment (SPA) with the FDA. In connection with the initiation of the trial, we expect to receive a $1 million milestone payment from Sigma-Tau in accordance with our collaboration agreement."

Soligenix's address and contact numbers will also remain the same. Soligenix's new web address is www.soligenix.com.

About Soligenix, Inc.

Soligenix, Inc. (Soligenix), formally known as DOR BioPharma, Inc., is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. Soligenix expects to begin a confirmatory Phase 3 clinical trial of orBec® for the treatment of a
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
2. Researchers prolong the plasma half-life of biopharmaceutical proteins
3. Emissary Capital Group Initiates Coverage on Sinobiopharma
4. PDL BioPharma Announces Conversion Rate Adjustment for Its 2.00% Convertible Senior Notes Due February 15, 2012
5. Pandesa ShareVault Enables Secure, Real-time Due Diligence for Biopharmaceutical Partnering
6. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
7. Enox Biopharma Will Present Its Unique Self-Sterilizing Urinary Catheter at the 49th Annual ICAAC Meeting.
8. Helix BioPharma Closes Private Placement
9. PDL BioPharma Provides Third Quarter 2009 Revenue Guidance of Approximately $71 Million
10. Helix BioPharma Announces $13.5 Million Private Placement
11. Helix Biopharma to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report analyzes the ... by the following Product Segments: Media, Sera, and Reagents. ... Canada , Japan , Europe ... America . Annual estimates and forecasts are provided for the ...
(Date:8/19/2014)... XenoTech announces an exclusive partnership with ... from bioactive small molecules. Based on an ... convenient and timely assessment of critical metabolite and ... of Commercial Operations, Christian Darabant, “the value of ... be measured directly by comparison with the approximate ...
(Date:8/19/2014)... Aug. 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" ... reported results of its Oral Amphotericin B (Oral ... The study, conducted by ImmuneCarta®, the immune monitoring ... effectiveness of Oral Amp B in reactivating ... individuals despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... , Aug. 18, 2014 ... of advanced consumer medical devices said that ... was interviewed by CEOLIVE.TV as part of ... entire interview is available at http://ceolive.tv/bioelectronics-corp-otc-biel/biel-videos/2282-ceolive-tv-interview-bioelectronics-corp-otcqb-biel ... Kotak explains to investors the unique advantages ...
Breaking Biology Technology:Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3
... (NSF) has awarded $6.5 million to the Center for Nanotechnology ... work regarding the societal aspects of nanotechnology for another five ... its first five-year award of $6.2 million to Arizona State ... of NSF,s initiative to support research and education on nanotechnology ...
... DIEGO, Oct. 14 Sequenom, Inc. (Nasdaq: ... a new clinical advisory board focusing on retinal ... will provide guidance to Sequenom and Sequenom Center ... of retinal care molecular diagnostics. (Logo: ...
... ... ... ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...
Cached Biology Technology:Arizona State University awarded $6.5 million to study nanotechnology and society 2Arizona State University awarded $6.5 million to study nanotechnology and society 3Sequenom Announces Formation of Ophthalmology Clinical Advisory Board 2Sequenom Announces Formation of Ophthalmology Clinical Advisory Board 3Sequenom Announces Formation of Ophthalmology Clinical Advisory Board 4Sequenom Announces Formation of Ophthalmology Clinical Advisory Board 5The World Market for Diabetes Treatments Now Available at ReportsandReports 2The World Market for Diabetes Treatments Now Available at ReportsandReports 3The World Market for Diabetes Treatments Now Available at ReportsandReports 4The World Market for Diabetes Treatments Now Available at ReportsandReports 5The World Market for Diabetes Treatments Now Available at ReportsandReports 6The World Market for Diabetes Treatments Now Available at ReportsandReports 7The World Market for Diabetes Treatments Now Available at ReportsandReports 8The World Market for Diabetes Treatments Now Available at ReportsandReports 9
(Date:8/20/2014)... who are poor experience higher cortisol levels in pregnancy ... the stress hormone, putting them at greater risk ... new research from the University of Colorado Denver. , ... Journal of Human Biology , is the first to ... the socioeconomic status of their mothers during pregnancy. , ...
(Date:8/20/2014)... for electronically manipulating the flight muscles of moths and ... those muscles. The work opens the door to the ... emergency response. , "In the big picture, we want ... moths for use in applications such as search and ... of electrical and computer engineering at NC State and ...
(Date:8/20/2014)... 2014  The second annual Biometrics UnPlugged Executive ... Tampa, Florida on September 15, 2014, ... Technology and Strategy at Samsung, and Philippe de ... of this year,s event is Mobility at the ... "Biometrics UnPlugged: Mobility at the Crossroads of Commerce ...
Breaking Biology News(10 mins):CU Denver researcher shows economic disparities impact infant health 2Research paves way for development of cyborg moth 'biobots' 2Biometrics UnPlugged: Mobility at the Crossroads of Commerce & Privacy to Feature Interactive Sessions with Samsung and Experian 2
... collaboration with colleagues from UC Berkeley and StrataGent Life ... pulsed microjet system engineered to deliver protein drugs into ... penetration injection systems cause. The research was published online ... Sciences. , The effort to create needle-free drug ...
... rise to a rare genetic disease, genetics researchers have ... broader role during human development, potentially in cases of ... of researchers identified two genes that contribute to Cornelia ... an estimated one in 10,000 children. The disease varies ...
... researchers from the National Human Genome Research Institute (NHGRI), ... identified a genetic variant that is a major contributor ... the April 6, 2007 issue of the journal Science. ... variant that accounts for differences in dog size is ...
Cached Biology News:Researchers design pulsed mircrojet system to deliver protein drugs without pain or bruising 2Gene found for rare disorder may reveal new pathway in mental retardation 2Researchers identify gene involved in dog size 2Researchers identify gene involved in dog size 3Researchers identify gene involved in dog size 4
... The ULS cDNA Synthesis and Labeling Kit ... hybridization experiments. First unmodified cDNA is made ... cDNA using an Oligo(dT) primer. Unlike other ... used in the reverse transcription reaction. This ...
... Dot Blot Kits overcome this limitation and ... a wide range in low-density protein array ... They are ideal for performing reverse-phase protein ... for the presence of low abundant antigens. ...
AC input: 50-60 Hz230 V...
... arraying proteins of interest with sensitive ... DiscoverLight Protein Array Kits allow for ... lysate or antibody in a low-density ... designed nitrocellulose membranes with a 384-grid ...
Biology Products: